0001217234-23-000178.txt : 20230808 0001217234-23-000178.hdr.sgml : 20230808 20230808161140 ACCESSION NUMBER: 0001217234-23-000178 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareDx, Inc. CENTRAL INDEX KEY: 0001217234 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 943316839 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36536 FILM NUMBER: 231151420 BUSINESS ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: 4TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415-287-2300 MAIL ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: 4TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: XDx, Inc. DATE OF NAME CHANGE: 20071010 FORMER COMPANY: FORMER CONFORMED NAME: EXPRESSION DIAGNOSTICS INC DATE OF NAME CHANGE: 20030203 8-K 1 cdna-20230808.htm 8-K cdna-20230808
0001217234FALSE00012172342023-08-082023-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 8, 2023
 
CAREDX, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware 001-36536 94-3316839
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
8000 Marina Boulevard, 4th Floor
Brisbane, California 94005
(Address of Principal Executive Offices) (Zip Code)
(415) 287-2300
Registrant’s telephone number, including area code
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 Securities registered pursuant to Section 12(b) of the Exchange Act:
(Title of each class)(Trading Symbol)(Name of exchange on which registered)
Common Stock, $0.001 Par ValueCDNAThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02 Results of Operations and Financial Condition.
On August 8, 2023, CareDx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 
104Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 8, 2023  
CAREDX, INC.

  By: /s/ Abhishek Jain
   Abhishek Jain
   Chief Financial Officer


EX-99.1 2 cdna-20230808_earningsrele.htm EX-99.1 Document
Exhibit 99.1
logoa.jpg

CareDx Reports Second Quarter 2023 Results
BRISBANE, Calif., August 8, 2023 -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the second quarter ended June 30, 2023.
Second Quarter 2023 Highlights and Other Recent Updates
CareDx received the industry’s first and only multimodal MolDX approval in transplant with HeartCare for Medicare patients.

CareDx received the industry’s first and only donor-derived cell-free DNA (dd-cfDNA) MolDX approval for lung transplant patients with AlloSure® Lung for Medicare patients.

Reported revenue of $70.3 million, a decrease of 13% year-over-year due to the impact of the Medicare Billing Article revisions.

Reported testing services revenue of $53.4 million, a decrease of 20% year-over-year. Archived growth in non-testing services business with revenues of $9.0 million for Patient and Digital Solutions and $7.9 million for Products, representing year-over-year growth of 33% and 17%, respectively.

Achieved over 80% adoption of new test requisition forms (TRFs) by the end of June, two quarters ahead of target.

Delivered approximately 37,500 patient test results for AlloMap® and AlloSure, a decline of approximately 17% year-over-year, driven by the impact of the Medicare Billing Article revisions and operational adjustments required of customers.

Collected over $20.0 million in incremental cash, driven by cash collections at 110% of revenue for testing services in the last three quarters.

Maintained strong balance sheet with $283 million of cash and cash equivalents, and marketable securities, with no debt.

“We are proud to continue our transplant innovation leadership, as the first and only company to receive Medicare coverage for multimodality in transplantation with HeartCare, and dd-cfDNA in lung with AlloSure Lung,” said Reg Seeto, CEO and President of CareDx. “A key focus for the second quarter was operational execution of the Billing Article revisions and we are pleased to achieve over 80 percent adoption rate for our new TRFs, well ahead of target.”
Second Quarter 2023 Financial Results
Revenue for the three months ended June 30, 2023, was $70.3 million, a decrease of 13% compared with $80.6 million in the second quarter of 2022. Testing services revenue for the quarter was $53.4 million, compared with $67.1 million in the same period in 2022. This includes approximately $7.8 million in revenue associated with AlloSure Kidney Medicare tests that the Company did not submit for reimbursement in the first quarter of 2023.
Total AlloSure and AlloMap patient results provided in the quarter were approximately 37,500, representing a decrease of approximately 17% as compared to the same quarter a year ago, and primarily attributable to the impact of the Medicare Billing Article revisions on AlloSure Kidney testing volumes.




For the second quarter of 2023, net loss was $25.0 million, compared to a net loss of $21.7 million in the same period in 2022. Basic and diluted net loss per share in the second quarter of 2023 was $0.46, compared to basic and diluted net loss per share of $0.41 in the second quarter of 2022.
Non-GAAP net loss was $9.9 million in the second quarter of 2023, compared to a non-GAAP net loss of $7.0 million in the second quarter of 2022. Basic and diluted non-GAAP net loss per share was $0.18 in the second quarter of 2023, compared to a basic and diluted non-GAAP net loss per share of $0.13 in the second quarter of 2022.
Adjusted EBITDA for the second quarter of 2023 was a loss of $10.4 million, compared to an adjusted EBITDA loss of $5.7 million in the second quarter of 2022.
Cash and cash equivalents and marketable securities were $283 million as of June 30, 2023.
2023 Guidance
For the full year 2023, CareDx expects revenue to be in the range of $240 to $260 million.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements with respect to expectations regarding its 2023 revenue. All statements other than statements of historical fact contained in this press release, including statements regarding the future financial position of CareDx, including financial targets, business strategy and plans and objectives for future operations, are forward-looking statements. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond our control, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, and the quarterly report on Form 10-Q for the quarter ended June 30, 2023 to be filed by CareDx with the SEC on or about August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.












Use of Non-GAAP Financial Measures
CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income (expense), net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP net loss, non-GAAP basic and diluted net loss per share, adjusted EBITDA, adjusted revenue from testing services, and adjusted total revenue. We define non-GAAP net loss and per share results as the GAAP net loss and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of contingent consideration; acquisition-related impairment charges and amortization of purchased intangible assets and related tax effects; costs involved with completing an acquisition; unrealized loss on investments; restructuring charges and certain other charges. We define adjusted EBITDA as non-GAAP net loss before net interest income, income tax benefit, depreciation and other expense, net. This release also contains adjusted revenue from testing services, which was prepared on a non-GAAP basis that excludes the $7.8 million revenue associated with the recognized AlloSure Kidney Medicare claims. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.





CareDx, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue:
Testing services revenue$53,414 $67,135 $115,198 $133,579 
Product revenue7,876 6,714 14,737 13,502 
Patient and digital solutions revenue9,011 6,785 17,628 12,969 
Total revenue70,301 80,634 147,563 160,050 
Operating expenses:
Cost of testing services15,324 18,230 30,620 35,858 
Cost of product3,926 3,887 7,992 8,286 
Cost of patient and digital solutions6,637 5,422 13,241 10,277 
Research and development20,233 22,632 44,590 44,512 
Sales and marketing21,630 26,950 44,861 50,098 
General and administrative29,327 25,232 57,359 51,791 
Restructuring costs848 — 848 — 
Total operating expenses97,925 102,353 199,511 200,822 
Loss from operations(27,624)(21,719)(51,948)(40,772)
Other income (expense):
Interest income, net2,871 478 5,537 667 
    Change in estimated fair value of common stock warrant liability
48 10 75 
Other expense, net(271)(553)(2,245)(1,376)
Total other income (expense)2,603 (27)3,302 (634)
Loss before income taxes(25,021)(21,746)(48,646)(41,406)
Income tax benefit (expense) 68 49 (56)61 
Net loss$(24,953)$(21,697)$(48,702)$(41,345)
Net loss per share:
Basic$(0.46)$(0.41)$(0.91)$(0.78)
Diluted$(0.46)$(0.41)$(0.91)$(0.78)
Weighted-average shares used to compute net loss per share:
Basic53,846,260 53,249,545 53,745,299 53,133,149 
Diluted53,846,260 53,249,545 53,745,299 53,133,149 





CareDx, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
June 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$87,786 $89,921 
Marketable securities194,887 203,168 
Accounts receivable51,625 66,312 
Inventory18,840 19,232 
Prepaid and other current assets7,676 9,216 
Total current assets360,814 387,849 
Property and equipment, net36,084 35,529 
Operating leases right-of-use assets32,118 34,689 
Intangible assets, net43,529 43,051 
Goodwill39,655 37,523 
Restricted cash584 522 
Other assets2,036 3,828 
Total assets$514,820 $542,991 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$9,880 $9,942 
Accrued compensation14,441 16,902 
Accrued and other liabilities50,175 49,131 
Total current liabilities74,496 75,975 
Deferred tax liability51 — 
Common stock warrant liability— 32 
Deferred payments for intangible assets4,224 2,418 
Operating lease liability, less current portion30,589 33,406 
Other liabilities247 249 
Total liabilities109,607 112,080 
Commitments and contingencies
Stockholders’ equity:
Common stock
52 52 
Additional paid-in capital923,514 898,806 
Accumulated other comprehensive loss(8,450)(7,503)
Accumulated deficit(509,903)(460,444)
Total stockholders’ equity405,213 430,911 
Total liabilities and stockholders’ equity$514,820 $542,991 





CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Cost of testing services reconciliation:
GAAP cost of testing services$15,324 $18,230 $30,620 $35,858 
Stock-based compensation expense(492)(566)(971)(585)
Acquisition related-amortization of purchased intangibles(329)(329)(658)(658)
Non-GAAP cost of testing services$14,503 $17,335 $28,991 $34,615 
Cost of product reconciliation:
GAAP cost of product$3,926 $3,887 $7,992 $8,286 
Stock-based compensation expense(274)(402)(634)(530)
Acquisition related-amortization of purchased intangibles(416)(437)(834)(890)
Non-GAAP cost of product$3,236 $3,048 $6,524 $6,866 
Cost of patient and digital solutions reconciliation:
GAAP cost of patient and digital solutions$6,651 $5,422 $13,255 $10,277 
Stock-based compensation expense(367)(391)(769)(583)
Acquisition related-amortization of purchased intangibles(255)(236)(503)(472)
Restructuring costs(14)— (14)— 
Non-GAAP cost of patient and digital solutions$6,015 $4,795 $11,969 $9,222 
Research and development expenses reconciliation:
GAAP research and development expenses$20,478 $22,632 $44,835 $44,512 
Stock-based compensation expense(1,704)(2,323)(3,666)(4,513)
Restructuring costs(245)— (245)— 
Non-GAAP research and development expenses$18,529 $20,309 $40,924 $39,999 
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses$22,178 $26,950 $45,409 $50,098 
Stock-based compensation expense(2,779)(3,907)(6,516)(7,030)
Acquisition related-amortization of purchased intangibles(606)(543)(1,201)(1,148)
Restructuring costs(548)— (548)— 
Non-GAAP sales and marketing expenses$18,245 $22,500 $37,144 $41,920 
General and administrative expenses reconciliation:
GAAP general and administrative expenses$29,368 $25,232 $57,400 $51,791 
Stock-based compensation expense(7,084)(5,004)(13,898)(9,986)
Change in estimated fair value of contingent consideration(67)(500)(488)(564)
Acquisition related fees and expenses— (186)(284)(329)
Restructuring costs and charges(41)— (99)— 
Non-GAAP general and administrative expenses$22,176 $19,542 $42,631 $40,912 
Total other income (expense) reconciliation:
GAAP other income (expense), net$2,603 $(27)$3,302 $(634)
Unrealized (gain) loss on long-term marketable equity securities(53)(21)857 486 
Asset impairments and write-downs— — 1,000 — 
Other charges (income)(11)28 17 
Non-GAAP other income (expense), net$2,557 $(59)$5,187 $(131)
Income tax benefit (expense) reconciliation:
GAAP income tax benefit (expense)$68 $49 $(56)$61 
Tax effect related to amortization of purchased intangibles(100)(107)(201)(220)
Non-GAAP income tax expense$(32)$(58)$(257)$(159)




CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin
(Unaudited)
(In thousands, except percentages)

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Total revenue$70,301 $80,634 $147,563 $160,050 
GAAP cost of sales25,901 27,539 51,867 54,421 
GAAP gross profit44,400 53,095 95,696 105,629 
Stock-based compensation expense1,133 1,359 2,374 1,698 
Restructuring costs14 — 14 — 
Acquisition related-amortization of purchased intangibles1,000 1,002 1,995 2,020 
Non-GAAP gross profit$46,547 $55,456 $100,079 $109,347 
Non-GAAP gross margin %66 %69 %68 %68 %




CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
GAAP net loss$(24,953)$(21,697)$(48,702)$(41,345)
Stock-based compensation expense12,700 12,593 26,454 23,227 
Asset impairments and write-downs— — 1,000 — 
Unrealized (gain) loss on long-term marketable equity securities(53)(21)857 486 
Acquisition related-amortization of purchased intangibles1,606 1,545 3,196 3,168 
Acquisition related fees and expenses— 186 284 329 
Change in estimated fair value of contingent consideration67 500 488 564 
Restructuring costs and charges848 — 906 — 
Tax effect related to amortization of purchased intangibles(100)(107)(201)(220)
Other charges (income)(11)28 17 
Non-GAAP net loss$(9,878)$(7,012)$(15,690)$(13,774)
GAAP basic and diluted net loss per share$(0.46)$(0.41)$(0.91)$(0.78)
Non-GAAP basic net loss per share$(0.18)$(0.13)$(0.29)$(0.26)
Non-GAAP diluted net loss per share$(0.18)$(0.13)$(0.29)$(0.26)
Shares used in computing non-GAAP basic net loss per share53,846,260 53,249,545 53,745,299 53,133,149 
Shares used in computing non-GAAP diluted net loss per share53,846,260 53,249,545 53,745,299 53,133,149 

































CareDx, Inc.
Reconciliation of Non-GAAP to Adjusted EBITDA
(Unaudited)
(In thousands)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Non-GAAP net loss$(9,878)$(7,012)$(15,690)$(13,774)
Interest income(2,871)(478)(5,537)(667)
Income tax benefit (expense)68 58 (56)159 
Depreciation expense2,052 1,162 3,860 2,102 
Other expense, net279 537 664 798 
Adjusted EBITDA$(10,350)$(5,733)$(16,759)$(11,382)

















































CareDx, Inc.
Reconciliation of GAAP Revenue to Adjusted Revenue
(Unaudited)
(In thousands)

Three Months Ended June 30, 2023
Testing ServicesTotal Revenue
GAAP revenue$53,414 $70,301 
Recognized AlloSure Kidney Medicare claims(7,771)(7,771)
Total adjusted revenue$45,643 $62,530 







CareDx, Inc.

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
investor@caredx.com


EX-101.SCH 3 cdna-20230808.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cdna-20230808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 cdna-20230808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 logoa.jpg CAREDX LOGO begin 644 logoa.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@ T@)3 P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HKD?''CO_A# M'LU_L[[;]J#G_7^7MVX_V3GK7)_\+R_ZE[_R=_\ M=92K0B[-GHTFJE M.%T_-?YGK5%8'@WQ1_PENAMJ/V/[)MF:+R_-\SH E>+_\+=\4_P#/6U_[\"LIU8P=F>E@\MKXR+E3MIW/>Z*\H\!_$+7?$/BR M'3]1>!H'1V(2(*<@9'->KU4)J:NC#%X2IA*GLZF]KZ!1115G(%%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13921"Y'! M"FOFF3QAXD$C :[J.,G_ )>7_P :QJ553M<]/ 9=/'75I<7"1S02SLR2*3R"">17M?_ A/ MAG_H!6/_ 'Y%<\E]8U6ECW*559*O95?>YM=/NZGCOPG_ .2@6W_7*3_T&O?Z MR['PSHFF70N=/TNUMIU! DCC (!Z\UJ5TTJ;IQLSP\RQD<9652*MI8****U/ M,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@!DW^HD_P!T_P J^49/]:_^\:^L:*PJTO:6U/7RW,OJ/-[O->W6VU_)GS+X M/_Y'32/^ON/_ -"%?3.X>H_.L7QG_P B3J__ %ZO_*OF>L>;ZOIO<]?V7]N? MO;\G+IW\_(^L\@]#17@'PG_Y*!;?]#F&"^I5?9\U]+[ M6_S"BBBM3SPHHHH **** "BBB@ HKSSX@?&GPMX 5K>XG.HZH.!86I!9?=VZ M)^//M7SYXB^/'Q \'M^FQS-LBM-,0M-)]7^\3],#VH ^M=7\0:/X?@ M$VN:I9Z=&W"M=3K'N/H,GG\*XC4/C]\.=/.#KWVD_P#3M!(_ZXKR#PQ^S3XF M\1E=3\=&US'_7*' M_P".5Z?:?#_PA8Q[+7PQI*+[V:-_,58?P9X8D4J_AS22",'-C'_\30!YG9_M M1> [E]L]OK%I_M2VR$?^..3^E;MC^T!\.+XD#73;D?\ /Q;R)_2M+4O@W\/M M5C9;KPO9+N.2T :%OS0@UY-XR_9700RW7@?5)"Z@LMC?D'%?$$B1Z-XATV\E<96&.Y7S"/]S.[]*WZ_.C5M(U#0M4FT[6+26SO M(&VR0RKAE_SZU]4?LLW[W7P\U*WED9S;Z@0 QS@%%(_#K0![?1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZKX@T;05C;7-6L=- M64D1F\N4BWXZXW$9K0KB_'WPJ\.?$=K63Q MTDUJK+%-:S;&"DY(P00>GI0! M?;XD>"5Z^+M$_#4(C_[-527XM> 8?O\ BS2_^ SAOY5X%\5OV=XO!WAJX\0> M&-1N+NTM,-<6UV%,B(2!N#* #@GD8''TKPF@#[I;XU?#I20?%=EP>P<_^RTT M_&[X'4K#G MI;7A/_HP-0!V]O\ $CP3=;?)\6:,2W0-?1J3^!-=%!<0W,0EMI4FC89#QL&! M_$5\^:M^R;I[[VT/Q+ M=MX'H5X?MG@$>] 'V917Q'H7QS^(?AFZ"-J[WJ1G:]KJ4?FC(XP3PX_!A7L_ M@S]J#0M7GBM/%ED^C3/Q]IC/F09]_P")?R(]3WH ]UHJ"ROK74K..[T^XBN; M>4;HY8G#*P]B*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K M)?Q7X>BD9)-X\TRZ&!Y.65[W_"QD^+8);GPAJD%M$\LLELZHB*2S''0 =:^>_^$1\1 M_P#0!U+_ ,!'_P *^G***E%5'=LG 9I/!0<8Q3N>$_#_ $R^\/>+X+_7K.XT MVS2-U:XNXFBC!(P 68 Z"BBB@D**** # MI7S?\:?C]+!IQG)ST*1'^;?EZUT_[17Q+E\)^'8_#VCR^ M7J>K1DR2*?FAM^02/0L00#[-7R+0!L^&?#>J^-/$UOI&D1F>\NWY9R<*.K.Q M]!U)K[2^&WPLT3X<:2J6,2W&IRH!=7[K\\AZE5_NKGL/09R:Y7]G/P"GAKP, MNNWUN%U/65$H9E^:.#^ #TW?>/KE<]*]BH **** "BBB@ HHHH \M^.?PRM_ M'/A&;4+*%!KFFQ&2WD YF0A^IKS[]DO40LOB;2W.&(@N$7Z;U;^: MU])D9&#R*XGPA\)_#7@?Q)>ZWH0NTN;U&CD22;=&JLX8@+@8Y Q0!VU%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/Q(B$W MPQ\1QL,AM.FSG_<-? 5?H!\0O^2;^(?^P=/_ .@&OS_H ^HOV30/^$:\0MW- MW$/_ !PU] U\_P#[)O\ R+'B#_K\C_\ 0*^@* "BBB@ HHHH X'XB_![PW\0 M[:66Z@6QU8IB/48$&\$#C>.-X]CSCH17QWXU\$ZQX"\0R:3KL&QQ\T4RC,#9["6-1J$ ,MA.>#'(!TS_=;H1]#U H ^1_A MU\5/$'PYU)6TV=KC37D#7&GRL3'(.Y']UL?Q#T&<@8K[.\&>,M)\=>'(=8T. M;?$_RR1MP\+]T8>O\^M? %U:SV-Y-:7D30W$$C12QN,,C*<$$>H(KN_@[\19 MOA[XV@FGF?\ LB\80W\0.1M)XDQZKU]<9'>@#[CHIL\U6]M[&U3&^>YE6-%STRS$"@"S1 M6=I'B'1=?21M"U>QU)8B!(;.Y2783TSM)Q6C0 4444 %4]6U6UT32Y]0U!RE MO 7(&3R< ?4BKE>:?&G4S!H-EIR-@W,QD8>JH/\2/RJ*DN6+9UX/#_ %G$ M1I=W^'4T_P#A;OA;_GK=?]^#7AFHSI;4JRJ;GW^ M#RZC@VW2OKW'P_Z^/_>'\Z^KH_\ 5)_NBOE&'_7Q_P"\/YU]71_ZI/\ =%=& M%ZGA<2?\NOG^A6U348=(TNXO[H,8;="[[!DX]JXS_AL&\\-SZ;*V7LI!_";5O[.\;1V[G$=]&T)]F^\I_3'XU[Y7H4)I-?/'Q,_:72TFFTKX?+'/(C% M)-4E7<@Q_P \E_B_WCQZ YS0![]J6JZ?H]H;K5KVWLH%ZR7$@1?7&37GVL_M M!?#K1UD"ZTVHS1_\LK&W>3=]'("'_OJO-OAY\'[SXI6,'C/XF:Y?WR78)M;4 M2X8H&(R6/W5)!PJ@>N>U>A-^SC\.6BV#2[E?]H7DF?YT 4M,_:=\ 7]SY5U_ M:NFIC_6W5H&7_P ALY_2O2?#WBO0O%=F;KP[JMMJ$2XW&%\E,]-R]5_$5\E_ M&/X*2_#?RM4TJZDO=$N)/*#3 >; ^,A6( !!P<$ >F/7@?"7BO5/!GB2VUG1 M)S%/"WS+_#*G=&'<&@#]":*I:-J<.M:'9:I;<0WD"3H"]<]\:_ OC3Q=IROX/U^6W@2! MDGTE9#$MUUR=X/.0<;6X]Z^-)X);:XD@N(VCEB8HZ,,%6!P0: /M#X6_&1/B M=XBU6RMM):QM;*%98I))=SOEL?, ,#\":]!UC7=*\/V)O=DG5-8U>)+6SCR2$?=G<5'+?3(]2>*[?Q'\#/ MBOXQN/[7\1ZE8W=\PP(9;H_NEZ[5PNU1GL./YT >FZG^TQ\/M/O5@MY=1U)# M]Z>TM<(GU\QE)_ &O0?"WC'0/&FF&_\ #.HQWT"MM?:"K1GT96 (_$5\*Z[X M'\3>&M3>PUK1+RVG7_ID75AZJRY5A[@FOHC]F3P-KOA^VU/7-;M9;(TCM MH)AM=PI)+E3R!V&>O7I@D ]]J&\O;73[5[F_N8K:!/O2S.$5?J3Q7 _%?XNZ M9\-=-6,*E[K5RA-M9!\;1_?DQT7/;JV"!T)'@?A_POX\_:#U=M2US57ATJW< MK]HD4^5$3R5BB! )Z9/TR: />]7^/?PYT@NC^(%NY4&1'9P22[O8,!LS]6KG M(?VI? LMPL;V6N0J3@RO;1E1[\2$_I70:!\!/A]H,2 Z*NIRK@F;46\TL?=> M%_#%;5_\*/ 6HP>5/X1TA%];>T6!OS0 T 1:#\7/ GB698=)\26C3,=JQ3AH M&)] ) N?PKLZ^/\ XZ?!NV^'S6VM>'GE;1KN7R6BE;E% ' M.?$+_DF_B'_L'3_^@&OS_K] /B%_R3?Q#_V#I_\ T U^?] 'U'^R;_R+'B#_ M *_(_P#T"OH"OG_]DW_D6/$'_7Y'_P"@5] 4 %%%% !1110 4444 ?&G[1WA MU="^+4]S"FV'58$NP0.-^2K_ (Y7/_ J\GKZ1_:VMTW>%KD#$A%S&3ZC]V1_ M7\Z^;J /MCX*^,(-5^"MAJ&IW*1?V6CVMW-(V @BZ$G_ '"AK<7XL^ 68!?% MVDDGI_I*UY9^S#:6^K_#;Q%I>I0"XLIKW;)$^=KAHP"/T%;WB7]F;P9JMC-_ M87VG1KT\Q2)(98P?1D;M]"#_ "H [U?B7X):,N/%.E%1U/VI?\:@?XK> XVP M_BW20?\ KY6OBGQGX,U?P+XBET?780DR#='(ARDR'HRGN/Y5L_"6Q\':IXVC MT[QZLWV6[7RK9TF,:),2,;R.<'IG.,GGV /MS1M2>!4'BWPIH7C#0VL/$]JMQ9QMYPW.4\M@"-P8$8P": ,^+XI M^!)O]7XLTENZ=X AN MKK3VN!#9(29'D. #MP,D%LX[XQ7NG@?]ENT^PQW?CV^G:Y)]"M-+T[4O!\^ZTU?183;PWZ(N^6!XR3D =< MD\D5[MHVHKJ^A6&I(I1;RVCN I[!U#8_6O'7\*WWBY[^S\+Z+K/A[2MZP?)>=5QN$=N?F#MT+X ()ZU[5;6\5G:0VUN@2*%%CC4?PJ!@#\J ):*** M"O!?B[J1O?&[6X/R6<*Q >Y^8G]0/PKWJOF/Q;=_;?&&JSYR&NG /L#@?RKE MQ3M%(^CX?IJ6(E-]%^9D5Z9H_P 'CJVB66H?VYY/VJ!)?+^R;MNX9QG>,UYG M7TSX._Y$G1O^O*+_ - %<^'A&;:D>UG6+K86G&5%V;?E^IY\?@D8%,O]O[O+ M^;'V/&<<_P!^G?\ "[PGR?\ "/YV\9^V_P#VNO5;G_CUE_W#_*OE%_\ 6-]3 M6M7]S;DTN<&6_P#"IS?7/>Y;6Z;[[6['I.N_%[^VM"O--_L3R?M,9C\S[7NV MY[XV#->:T45R2G*;O(^CP^%HX6+C15D_7]33T?PYJVOB8Z/9/="''F;"!MSG M'4^QK2_X5WXL_P"@+-_WTG^-=O\ [_4ZW_O0?\ L]>KUU4Z$9P4FSY_'YS7 MPV)E1C%-*W?LGW/F-+:_\*>)K0ZE UM<6\J3%&()QG/:OIM6#J&4Y!&017@W MQ>_Y'U_^O:/^M>P^$+LWW@W2;ACN9K6,,?4@8/ZBKH>[.4#DSANOAJ.)>[6O MSU-FBBBNL^9"J&O:>=6\.:EIPQF\M)8.?]M"O]:OT4 ?FZZ-'(R."K*<$'L: MW/ VHC2?B#X?U!SA+;4K>1S_ +(D7/Z9K?\ C/X3F\(_%'5+Y(7ZC->!>'_V8/&6HWR#7)K+2;3(\R3S?.DQ_LJO!/U8?C7U MW10!F^'M$MO#7AO3]%L=QM[&W2!&;JP48R?<]?QK2HK/U;7M)T&W\_6M2M;" M/!(:XF5,XZXR>?PH XOX]013_!'Q#YZ[MD<3J<6*-A%"$D5R=Q W9VX&W(]_7YBH ^]_A8A3X3>%U M8DG^S(.O^X*ZRN>^'\?D_#CP]'_=TV ?^."NAH *^ OB0@3XH>)548 U2X _ M[^&OOVO@/XE_\E3\3_\ 84N/_1AH ]+_ &5M,ANOB#J5_*BL]G8$1DC.TNP! M(]\ C\37UC7RY^R;_P C3X@_Z\H__0Z^HZ "LKQ/K]MX7\+ZAK=\?W%C TI& M?O$=%_$X'XUJUXI^U)JLMG\,[2PB8JM_?J),?Q*BEL?]];3^% 'RWXE\1:AX MK\1WFM:O*9;J[D+MZ*.R@=@!P*]I\+_M+VWA7PMI^B6/@=?*LH%BW+J6W>0. M6(\D\DY)Y/6O'?!30IX^\/M=A3 -3MC*&&05\UZ?:6-G'.)RL&YF=@"%R2>@W'H*\XMK2YO+E+>SMY;B>0X2*)"S,?0 P/2B@#)\*17D/@W18M5#"^2P@6Y#_>\P1KNS[YS6M110!SGQ"_Y)OXA_[! MT_\ Z :_/^OT ^(7_)-_$/\ V#I__0#7Y_T ?4?[)O\ R+'B#_K\C_\ 0*^@ M*^?_ -DW_D6/$'_7Y'_Z!7T!0 4444 %%%% !1110!\Q?M::@DFL^&]-4_O( M+>>=Q[.RJO\ Z+:OGFO1?COXC3Q)\7M4D@LZK:Z;IL+3W=U*L4,:]68G % 'UE^R_I,EC\*YKZ92HU"_DDC/JBA4S_P!] M*_Y5[/61X3T"+PMX1TS0[<@I8VZQ%A_$P'S'\3D_C6O0!QOQ,^'&F_$CPRUA M>!8+V'+V=X%RT+XZ'N5/\M7VNAZ'N&![@C MD'TK]$:\W^,7PHM?B/H/FVH6#7+-2;2<\"0?\\G/H3T/8^V<@'%?L_\ QD&M M6\/A#Q1< :A"H2PNI&_X^5 _U;$_Q@#CU'N.^"-]U+-(( M+V2V.YI7SCR%Q[_>_+L:^=;NTO=%U66UNXY;2]M)2KH?E>-U/Z$&O>?V6E\+ MOK.I/?$-XFZVOG=/)Q\QC_VL]<\XQC^*@#TKX-?!JS\ :2 M$ BU!_@3W]6[].E>K444 %%%% !1110 4444 %?)\\AFN))3U=RQ_$U]85\J MZG;-9:M=VKC#0S/&?P8BN+%=#ZSAQKFJKT_4K5W.F_%K7=*TNUL+>TTYHK:) M8D+QN6(48&<..:X:BN2,I1V/IZV'I8A)58WL>@O\9_$,D;(;/3,,"#B*3_XN MO/BYHHHE.4MV*AA:.'O[*-KFOX:\-WGBG4WL=.:)94B,I,K$# ('I[BN MI_X4WXC_ .>UE_W]/^%+\&/^1VN/^O%__0TKW*NJC1C.-V?/9IFF(PN(]G3M M:RZ'DF@2_P#"I/M$7B-?.;4MK0_9#NQLSG.5U,JDJ4N2.R-L-@*&84EBJ_Q2WMIMI^AT?COQ#:^)O$ MS:C8I(D1B1,2 Y'TKV7X9N7^'NFY_A#@?\ ?9KYWKZ-^'=NUM\/]*5Q@O$9 M/P9B1^A%/#MRJ-LSSRG"C@H4X[)JWW,Z:BBBN\^,"BBB@#S;XU_#)?B)X3!L M0%UG3\R6;' \P?Q1$^AQQ[@>]?%-Q;3V=S);W<,D$\3%)(I%*LC#J"#R#7Z/ MUY)\7O@=8^/DDU;13'8:^J\N>([H#H'QT/HWYY[ 'B'P&^*0\!^)6TW6)@FA MZDP$K-TMY>BR?3LWM@]J^R(Y$FB62)U>-P&5E.0P/<&OSR\0^&M8\*:M)IOB M"PFLKI.=LB\,/[RGHP]Q7J'PD^/=_P""EAT7Q()=0T,';&X.9;0?[.?O+_L] MNWH0#Z_HK)\.>*-%\6Z6NH^'M0AOK=N"8VY0_P!UAU4^QK6H **** "BBB@ MKQ?Q9\I1OA?V[=_2O-_P!FKPI/K_Q%F\1W:L]MI*%S M*_.^=\A1[G&XG\/6@#ZTGN(;6WDGNI4AAC4L\DC!50#J23T%>'>,/VH=!TF: M:T\*V$FLS)E1I=0QI<>:[.02<@ MY//%?,U?6G[4VJ6]O\.+'36E47-U?K(D>>2B*VXX],LOYU\E@X.: /T-\*1^ M3X.T:/IML81_XX*UJQ_"-[#J/@O1KRV8-%-8PLI'3[@K8H *^ _B7_R5/Q/_ M -A2X_\ 1AK[\KX ^(T@E^)WB1P00VIW!R/^NAH ]<_9-_Y&GQ!_UY1_^AU] M1U\M?LG.H\6Z^A/S-9(0/H__ ->OJ6@ KPW]JG3Y+CX>Z;>QJ62UU !R/X0Z M$ G\0!^->Y5B^,?#5MXP\'ZEH-Y@1WL)0,1]QQRK?@P!_"@#\^(Y&BE22,X9 M&#*?0BOOOX>>+K7QOX%T[6;60-))$$N$SS'*O#J?QY]P0>]?"GB#0-0\,:]= MZ/K$#07=K(4=3T/HP/<$<@UUGPJ^*NI?#36F>-3=Z5=,/M=F3C./XT/9@/P/ M0]B #[EHKF?!_P 0O#7CJS\[P]J<4TBJ&DM7.V:+_>0\_B,CWKIJ "BBO*OB M5\N:^\JQFUB?*19/1BN?F[!1SSS[@'JM%5M.GN+K2[6XO;4 MV=S+"CS6Q M'?&UUHNHRK#;:TB)$[G $Z$[!_P(,P^NVOKJ@ HHHH ***"<=: "O./C1\2X M/A_X/D2VE_XG5^C164:GE.QE/H!V]3CWQG_$;X_>&_!UO/::--%K6LK\JPP/ MNBB;_;<<@SZ\3_"?]G:WT M&6#7/' BN]00AX; ?-% >Q8_QM[=![U[UTZ4 %%%% !7E_QF^+UM\.](^Q:< M4GU^[0^1$>1 O3S''\AW/M5[XL?%?3OAOH9"-'8^.BC]>@[ MX\'^$7P^U#XL^-+GQ7XO=[C389]\[R<_:YN"(Q_L@$9]L#OP 4=-^"/C#QKX M+O?&US<[[^Z)N8;68$RWB\EGS_"3_",<^W%>7V%_?Z%J\-[832V=]9R[HY%^ M5HW!_P @BOT71%C14C4*JC"JHP /2OGC]H+X-_;(Y_&7A:W_ -(0%]1M(D_U MB@,]CGA MA^8/YBOH*N/^)/A9O$GAPO:KF]L\R1#'WQ_$OX_S%85X<\-#U\HQ2PV*3EL] M&?/E%!!5B",$<$&BO,/T,**** -[P?XH?PEK,FH1VRW)>!H=C-MQDJ<_^.UV MW_"[[G_H#1?]_C_A7E=%:1JSBK)G#7R_#8B?/5C=_,Z?QIXTD\8S6CRV:VOV M57 "N6W;L?X5S%%%1*3D[LZ:-&%&"ITU9(LZ;8RZGJEM90#,EQ(L:_B:^I+2 MVCLK*"U@&V*"-8T'H ,#^5>4?"#PHS3-XAOHL(H*6FX=3T9Q_+\Z]=KOPT.6 M/,^I\9GV*56LJ4=H_G_P HHHKJ/G0HHHH **** ,GQ#X6T3Q7IYLO$6F6]_ M00!*O*Y[JPY4^X(KPOQ5^RG;3/)/X.UHVVAJPZ$:;""/_ !V@#Q+4?VLX?+QI'A:0OG@W-T,?DJ_UKB/$ M/CSXN?$C-O;:?J-O8S+@6VFVDD<;CW?JWXMCVKZ[M=-L;! EC96]LHZ+#$J M?D*LT ?%^@?LZ?$#6\-<6-OI$1&0^H3[2?\ @*!FS]0*^IOASX%M/A[X-MM% MM'\Z4$R7-QC'G2GJ?IT ]@*ZJB@#G?'?@^S\=^#KW0;\^6LZAHI@,F*0*O $A'A^_Q:LVZ2SG7S(7/TZ@^ZD'WKU_2OB5\;?B';I;^&]&M--BE(SJ M*6IC0*>^Z5F&/]T$^E?10T?3!=?:1IUIY_\ SU\A=WYXS5R@#Y]O/V:+_7=- MN+[Q/XPN;_Q%)'^[E8%H5;^Z2WS%?ICUQVKYY\3>#M?\'Z@UIXBTR>S<,55W M7,;_ .ZXX;\#7Z$4V2*.:,I,BR(>JL,@_A0!\3?#SXS>,_!=F-%T1(=3MG;] MQ9W,+2F-B? -U\6/%&OP^(O%ICT31K6-BFD0PA&O"5(&0Q+ M#G!RQZ@8'6O6;73K*Q!%C9V]L#R?)B5,_D*LT > ZI\9?B=>0SP:'\.+FUD) M*I--#+(4[9Q@ G]*\,N?AC\0;RZEN;GPOJLDTSEY'-N%+F0-I4FIVB\K=Z>#*K#W7[P/ MU'YU]OT4 ?G'_I>F7O\ RVM+J%O>-T/\P:Z6S^*/CJRA6"T\5:JJ#A4^T,W\ MZ^\;BTMKM-MU;Q3KZ2(&'ZU':Z7I]C_QXV-M;?\ 7&%4_D* /D#2[/XU^/E6 MTCNM>:UD(#2W4S01 >I)QD<]LU[;\+/@+I?@2X35M:ECU;6P,H^W]U;GN4!Y M)_VC^ %>N44 %>2^.?BMXN\-^+KK2-"\ W>JV\ 0I> .4ER@8XVJ1P21U[5Z MU10!\E>/M:^,'Q(LET^\\*WMEIH8.;6UM'42$'(+EB2V/3@=\5Y__P *I\>? M]"IJG_@.:^]:* /@"X^'?C*TYG\+ZLN/2T<_R%>A>%?BM\6_"-JMI-I5]JEH M@ 2/4K"5FC'LX ;\R17U[10!\WK^TYXCB8+=>!2I[@/(/YK5A?VD_$UR ;+X M?7$OT,K?R2OHBB@#YTE^,WQ"/CQ\0F MV>(+V6RM)5Y6ZN4@BQZ&.+G\UKZGHH ^>O#G[*5A!)'+XJUV6[VD%K>R3RU; MV+MDX^@!^E>V>&_"&@>$;+[+X!I([:,_-*0,A1]:\(U3XO_%K5;)X?#_P^N-/D<$"XDMY) M63W ( S]01[5]"T4 ?"NJ?#[XEZWJ4NH:OX?UJ\NYCNDFFB9F8U[/\,O'?C7 MP[:Z%X2OOAU22<\\U]!T4 !Z5X;??&GQ_]LN+> MP^%]ZPC=D!E$AS@XSPN#^%>Y44 ?">I?#?QYJ>J7-\?!M_ ;F5I3%#:LJ)N. M<*.PYJ]X:\*_%3P9K":MH&@ZO:7$?4K;DJZ_W67HP]J^WJ* /"=-^-7Q"22W M@UGX97KR,RH\ENDB D]P"IQ^=>["BB@ HHHH **** "BBB@#RGXC_#AYY9=; M\/P[G;+W-J@Y8]W4>OJ*\B(()!&".H-?6=<=XJ^&ND>)&:YB_P!!O3UFB7Y7 M/^TO?Z\&N.KA[OFB?49;G7LHJEB-EL_\SY]HKK]8^&/B3296\NT^W0CI+;'= MGZKU'Y5S%S87EDV+RUGMSZ2QE?YUQRC*.Z/JZ6(HUE>G),KT4^&"6X?9!$\K M?W44D_I6]IO@/Q+JK*+?2IT5OXYQY:C_ +ZI*+>Q=2M3I*\Y)>ISU=IX$\ 7 M7B>Z2[O5:'2D;YY.AEQ_"O\ 4UVOAKX/V5A)'<^()EOI5Y\B/(B!]SU;]*]( MCC2&)8X45$0855& !Z8KKIX=WO,^9S#/(J+IX;5]_P#(;;6\-I:QV]M&L4,2 MA411@*!VJ2BBNX^0;;=V%%%% @HHHH **HZ;K>F:SY_]E:A;7GV=_+F\B4/Y M;>C8Z&I[V^M=-LI;S4+B*VMH1NDFF<*J#U)/2@">BH+*]M=1LHKNPGCN;:9= MTH(ZU/0 4444 %%%% !116-J?C#PYHUZ;35ME %BBN;_P"%B^#/^AITG_P,3_&G1_$+ MP?+(L<7B?2G=R%55NT))/0=: .BHHHH **** "BBB@ HHHH ***J:CJNGZ1 MDVJWD%G%)((D>>0(&<]%!/AH **** M"BBB@ HHKE=3^(_A[2-:72;Y]06]=F6.)-,N'\TJ,ML*H0P YR,T =516#I/ MC70=;\07>B:?>%]2LXUEGMWA=&16 (^\!ZC([9YJ30O%^B>);_5+/1+T74^E M3>1=@(P$;Y88R1AN5/(STH VJ*** "BBB@ HHHH **** #H,4444 %%%% M!1110 4444 %%%% 'B&J#_A4GQW@U6/Y?#GC ^3= \+;W.>&_$\_1F]!4_Q? MO)_'/C'1OA=HLA N'6\U>4?=B@4Y"GWXSCUV>M=S\4O"UIXO^'.JZ?> !XX6 MN+>4CF*5 6##]0?8FN#_ &;]%-UX;O?&NJW,E]K&K2F!IY3EEBC^4#/J2,D^ MRT =YXC\<>%/AKIUCI^HW!B81+%:6%K$99611@80= .IP*=X/\ B9X:\;SS M6NC74B7T W2V5W$8IE7UVGJ/IFN,^&4,/B;XO>/?$VIQK-=Z??\ ]EV>\9\B M*,LIVCL3M!_/U--^,UM%HGC+P+XIL$6&_75TL9)$&#)%)G*GU'WO^^C0!Z2W MBS2%\:+X5,[?VLUI]L$/EMCRMVW.[&.HZ4OB;Q5I/A'3X;W79V@@GN$MD98V M?,C9VC 'L>:\\F_Y.XM_^Q8/_HUJD_:&_P"1%TC_ +#MK_[-0!W>N>,=%\.: MMIFG:O=&"XU20QVH\LE6(QG+#A1SU-4_"_Q%\.>,M8U#3O#EXUZ^G@&:98R( MCDD?*Q^]TZCBO-/C_HO_ D7C3P%HYE:%;V\DA:1#@JI*9P?IFO9='T33?#^ MEP:=HUG%9VL"!$CB7' ]3W/N>30!>KPR]\.:1XH_:MU.Q\0:?#?VJZ"DJQ3# M(#AHP#]<$_G7N=> >(-/\1ZE^U'J,/@_5X-(OAH:,T\\ E4QY3*X]6&ZMF*-&RJ2"><$9'-2_"+QHUU\$;#7?%M^ MD2VHDBFO+AL;E1B%)/M4+KX9?$#Q-;-I_C#XB;M+DXGM].L5B:9>Z ME^, ^F"#Z5T/B?P[X$\/?#&+2_$L$4'AS3=A2-W89<'(^[RS$DY'?)H S8/C M_P"!9KM(WN+^"VD?8E]-8NMN?0[L9 ]R*['Q%XOT7PMX<_MW5[O9IQ* 31(9 M V\X4C;G(.>M>2>*_B)>>+?A[JMIX3^'M[/H)LI%.HWNVVAC0*?GC0@[\8XP M1TK(\5.\O[&>C%F+-MMP"3Z2D"@#U\_%#PJWBY?#5O?MP?# MOP3IO@OPA96=I"CW4D2RW=TRY>>5AEF)ZXR>!V%2)@&R ,<8QTQ0!Z9XA\5:1X7\.OKFKW.S3TV9FC0R9#$!2 N<@Y%94 M?Q.\+7'C"T\,6E^;G5+E=_EPQEEB&W=\[= <=NOK7CVKQ:Q;?L>FSU^TN[.[ MMIEA6*\B:.14$XV9# '&#@>PKUSX8^"]-\'^"K"*UA1KR>%9[N[89DFD89)+ M=<&4\4Q!]0EOMND$QNVV?*\Y7@?P]>*ZRO)?C#_R M4+X8_P#8<_K'0!W6O^.?#_AC6+#3= M[UB&P6]NHDGD\J&]FM'2WE;L Y'ZD 5SGQ7TNRUGXW_#ZQU2VCNK64S>9#(, MJ^,'!'<9'2MK]H&RME^!.M;;>-?LQMFAVH!Y9^T1K\OIP2/QH ]/ZU4U32K' M6],FT_5K:.ZM)QMEAD&5<9SS3-#D:7P]ITDC%G>UB9B>Y*"KU 'S]\?OA[X3 M\-_"]]0T+0;2QNQ>1()H5(;:O%<_P#M,_\ )'9/^OZ#^M>A:O\ \B#??]@R3_T4: .H4=![G KSO]FSP9I]K\/8/$MS#'<7^H/(L4LB[C!$DC+L7/W:C!!& M#C.[&,\=.IKR/4]:U_6/CC\/]3UGPBWAC?/<0PO)<+)-- M;.O:18:S^UAI<6J6L=U%#HIG2.5=RAU9MIQWQF@#J]"^-7@[7]=ATFWN;NUN M+D[;5KRU>%+@^B,?7MG&?K6[XP\=Z!X&LH;CQ!=F)KAMEO!%&9)9CZ*HY[]> ME<#^T-%'%H'A6XC14FB\0VZHZC!4%7) _(?E3OB;HOB32_B9H?C_ $'1?^$B MM]/LVM9].0_O$R6/F(,')(?L"?E]Z .J\*_%CPIXNU(Z;87&^@.:N>(/B-X7\+:V=*U[4A9W0LOMV'C8KY6XKP0.264@*.3Z5Q^@_$ M7X>^//%^FIJ>F2:=XELI#]DBU.V\N5'(P55NA/H#WY S5;7]+LM4_:RT5=1M M8[E;?PWY\:RKN"N)I0&QZC)Q^= '2>'_ (S^#_$.M1Z5%6LX'S1L MC G!]QD5RGQ:U&75_@=X)U*X.9;R^TVX<_[3PLQ_4T >N>)/%&C>$=)?4O$5 M_%96JG 9\DN?[JJ.6/L!7(Z/\:=+/SQ5 MGXFW?@;2(=,UOQXB226,Y>PCP7=Y,<@(.&['G@<5Y3\8O&NL^+?AG*Y&\^._@6SU-K5KZZE@23RY+^&T=[9&SC!<#GGN,BN>^.%K%J7 MA#P):7JF2&ZUVSBE7)&Y6C8$9'/0FNY\=:1I]I\)==T^ULH(;2+391'#'& J M@(<8'X4 4/BIXUT31/AW>B[NF8:QI\\5E);QM*LA,1P=R@@#YAR>*Y[X&?$# M0;[P;H/A6&>X;5H;5MZ-;.$X)8_.1M/'O4_AK][^RFC2_.5\/7 !;G&$<"MS MX*1H/@UX:<(N[[*><<_?:@#O*\8^*4UUXZ^*&B?#.TN9+?3GA^WZN\;8+Q@D MB/\ \=_-U/:O9Z\9T_\ <_M@:H)^#/HB&'/< )G'X@_E0!UE[\&/ -[H;:9_ MPCEG FS:L\*;9D./O;^I/US5;X/:=XJT'PW>:'XNCD:+3KIHM.NI74F:W'3@ M$D 8XSV/M7H=5K@V=W9W,%Q)$\&QHYQOX5W% '!ZM\<_!>E:I-8QW-Y MJ,EN=L\FGVC31Q'T+#@_AFNO\/>)]'\5:(FK:!?)>6;9^= 05(Z@J>0?8BO+ M]%^(GA[1[=_#?P@\'7WB)+9VW/:CR[<$DY+3OG/U/4=ZB^!+78U7XAQ7UBFF MRC4Q(]A$X9+=V#EE4CCT''I0!UEY\;? UEX)+=S-*5.UL) MC( /)6Y"Y^Z2Q8G']:I6_BQ;/\ :"\6ZK?^&-<\136 CLK/ M^S+(W/V1,-+V2QTJZFAU")=S65Y"89=O\ > /4 M?0G%5_%%C=S_ !<\"W<-M+);6PO_ #YE0E8MT "[CT&3P,UYQXIUZ_\ %7Q M\':SH/@+Q7IFH:?J4:W-W=Z2\:-:NP#JS#/ &>O !:O?Z /#=8T?Q+I7BSQ- MXJ\.:;/+?V^K+%%&8R/M-O- D;%>/F"N$;C^X?2NI^%_A23PEXC\1V/D2K;K M!8*EPZ$"XD$;^8X/H M]_K[ ^UT4 >/>.6OO!OQOTSQS+I5[J.B2:4=/N6L8C+);OO9@Q7TY7GZ^V>> M^)OB;7_B)H^FIX>\(ZI'HEOJEO(]U=6[+-,P)^Y$,G8!G+'VKZ"HH \K^)VF M7]Y\4OAW MZ;&"QN(AU&!U],?[1KU2B@#Q?Q-\2M0\8^$+_1O 7@[5Y7GLY$GGOK4P16R; M#E0/XWQP%'?'6L77M&U:Y_9(TG3(M*OFU"-H0]H+9S*,3'.4QGISTKZ"HH @ ML@5L+=6!!$2@@]N*\9UW6CX$_:,O_$&L:7J8'0X./]P^ M_(KVVB@#R'XA)=>(_%GPPU?2].OGM?[26XE)MFS A*',@'W/QKI_C+9W6H?! M_P 06MA;375Q) @2&&,N[GS%/"CDUV]% 'DWBCP3JOB/X+>&QHZ-!K^AQVM[ M:1R#:3(B#,9!Z$^A[@4D7QR9-+%O>>"_$2^(@NQM/CL24:3U#_W,]\9]C7K5 M% 'C?Q"@\7Z_^SS:" 0,Y8#KBO6-'1H]#L4D4JR MVT896&"#M'%7** "O+OBOIM]?>._AS-965Q<16NL^9/)#$SK"N8_F8@?*.#R M:]1HH \K\>Z9?W7QR\ WEM97$UK;&?SYXXF9(LCC 3^%>@T4 4-"1XO#NG)(K(ZVL096&""$'!% M7Z** /*_VBM,O]6^$\EMI5E<7MQ]MA;RK:)I&P,Y.%!.*[S5(I'\$7D*1LTK M:*M5\3Z!J=[;:RZR6.I65J9]JX_U?'3L,?[([*/&'Q5\#:Y/X4OM-T&TOY4MS/"QN/G509)5&1&OW<9]#S72W6F7[?M1V6 MHBRN#8KH31FZ$3>4'W'Y=^,9]LUZI10!Y7\>],O]4\.>'8]-LKB\>+7[>21; M>)I"B!7RQ ' &1S6SXU\8^)?".O6=Q!X9EUCPVT1%U+I^9+J%\]=G=">,]6'Q@U;0-.\(^&]4@GM-0BN;C6[RS, M(UZJ&/)/.<>JCKU%CQ] MK.IZ!^TSI>HZ1H\VL-%X;'GVL!'F&+SY=S(#U8<<=Z]SK@;OPIJLO[0%CXJ2 M%#I,.A&R>7S!N$OFNV-O7&&'- ''^-/&6H?%70SX.\%>']9@;4)$2_OM0M#; MQVL08,P))Y/&"/3.,YK3^,_AVY3X9^'-(T2RN+P6&J6:!+>)I&6.-&7<0 < M<$?&,^C76M:)IBR1W4%M%YK0L7$BX6&,99N<$GL :^@J* /)/BGI]_J M7AOX?_8K"ZG:'7+&:9(X69HD"'+, /E [D]*[SQW!+<_#[7H+:)YII+"94CC M4LS$H< =36_10!YEX5TF_\ ^&:8]*>SFCOWT2>$6TD963>5UU2S@=)C/9,D2E23]\^H/%>NT4 %>5_%CPCKO_"0Z-X] M\$0?:-:T;,J44 >1-\>3+8FWL? OB9]=*[19/ M9X17]WSG;[[?RJ+PW\.-?M_A9XLDU-U'BGQ0DL\R*W$18';%GUY.>W..V:]B MHH \+\!?$?\ X13P)8^%X? VO'Q!9IY36<5EMCEDS_K&D/ ![G%:GP;LO$%M MXB\?3>*=,>QO;V[BN"%C;RF+*Y(C8C#8R <$U[!10!YK\ M/O=+^$MG;:G9S MV=PMS<$Q7$31N 9"0<$ UBZY;ZU\,?BQJ'B[3]'NM9\/:]$@U"*Q3?-;2K_' MM[CO^)Z8&?9** /+8OBCK?B[7=/T_P >'+U+8S*U_J6KVK10Q1?Q!1G+-_7 M'UKU*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
Aug. 08, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 08, 2023
Entity Registrant Name CAREDX, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36536
Entity Tax Identification Number 94-3316839
Entity Address, Address Line One 8000 Marina Boulevard, 4th Floor
Entity Address, City or Town Brisbane,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94005
City Area Code 415
Local Phone Number 287-2300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol CDNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001217234
Amendment Flag false
XML 8 cdna-20230808_htm.xml IDEA: XBRL DOCUMENT 0001217234 2023-08-08 2023-08-08 0001217234 false 8-K 2023-08-08 CAREDX, INC. DE 001-36536 94-3316839 8000 Marina Boulevard, 4th Floor Brisbane, CA 94005 415 287-2300 false false false false Common Stock, $0.001 Par Value CDNA NASDAQ false 2023-08-08 EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !S@0A799!YDAD! M #/ P $P @ &<$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" #F$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.caredxinc.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cdna-20230808.htm cdna-20230808.xsd cdna-20230808_earningsrele.htm cdna-20230808_lab.xml cdna-20230808_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cdna-20230808.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "cdna-20230808.htm" ] }, "labelLink": { "local": [ "cdna-20230808_lab.xml" ] }, "presentationLink": { "local": [ "cdna-20230808_pre.xml" ] }, "schema": { "local": [ "cdna-20230808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cdna", "nsuri": "http://www.caredxinc.com/20230808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cdna-20230808.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.caredxinc.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cdna-20230808.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.caredxinc.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001217234-23-000178-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001217234-23-000178-xbrl.zip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end